

Direct Line: 01623 672232
Our Ref: 139
E-mail: sfh-tr.foi.requests@nhs.net

King's Mill Hospital
Mansfield Road
Sutton in Ashfield
Nottinghamshire
NG17 4JL

13th August 2024

Tel: 01623 622515
Join today: www.sfh-tr.nhs.uk

Dear Sir/Madam

Freedom of Information Act (FOI) 2000 - Request for Information Reference: Colorectal cancer

I am writing in response to your request for information under the FOI 2000.

I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below. Please accept our apologies for the delay.

Home, Community, Hospital.

Patient Experience Team
01623 672222
sfh-tr.pet@nhs.net



We are proud to
be a smoke-free
site

Chair Claire Ward
Chief Executive Paul Robinson

FOI Request / Question	Question Response	Is there an exemption?	Exemption	Exemption Details																																																																																															
<p>1. In the past 3 months, how many patients have been treated for Colorectal Cancer [CRC] with the following regimens?</p> <table border="0" data-bbox="96 544 521 1385"> <tr> <td>Regimens</td> <td>Total</td> </tr> <tr> <td>CRC Patients</td> <td>Metastatic</td> </tr> <tr> <td>CRC Patients</td> <td></td> </tr> <tr> <td>Aflibercept plus chemotherapy</td> <td></td> </tr> <tr> <td>Bevacizumab plus fluoropyrimidine-based chemotherapy</td> <td></td> </tr> <tr> <td>Capecitabine</td> <td></td> </tr> <tr> <td>CAPIRI</td> <td></td> </tr> <tr> <td>CAPOX</td> <td></td> </tr> <tr> <td>Cetuximab with FOLFIRI</td> <td></td> </tr> <tr> <td>Cetuximab with FOLFOX</td> <td></td> </tr> <tr> <td>Cetuximab as a single agent</td> <td></td> </tr> <tr> <td>Cetuximab with Encorafenib</td> <td></td> </tr> <tr> <td>Irinotecan as a single agent</td> <td></td> </tr> <tr> <td>FOLFIRI</td> <td></td> </tr> <tr> <td>FOLFOX</td> <td></td> </tr> <tr> <td>Fluorouracil (5FU) as a single agent</td> <td></td> </tr> <tr> <td>Oxaliplatin as a single agent</td> <td></td> </tr> <tr> <td>Nivolumab with Ipilimumab</td> <td></td> </tr> <tr> <td>Panitumumab with FOLFIRI</td> <td></td> </tr> <tr> <td>Panitumumab with FOLFOX</td> <td></td> </tr> <tr> <td>Panitumumab as a single agent</td> <td></td> </tr> <tr> <td>Pembrolizumab</td> <td></td> </tr> </table>	Regimens	Total	CRC Patients	Metastatic	CRC Patients		Aflibercept plus chemotherapy		Bevacizumab plus fluoropyrimidine-based chemotherapy		Capecitabine		CAPIRI		CAPOX		Cetuximab with FOLFIRI		Cetuximab with FOLFOX		Cetuximab as a single agent		Cetuximab with Encorafenib		Irinotecan as a single agent		FOLFIRI		FOLFOX		Fluorouracil (5FU) as a single agent		Oxaliplatin as a single agent		Nivolumab with Ipilimumab		Panitumumab with FOLFIRI		Panitumumab with FOLFOX		Panitumumab as a single agent		Pembrolizumab		<p>Can you please provide the total number of patients treated for CRC with each product and the total number of Metastatic patients treated with each product for CRC in the table below</p> <table border="1" data-bbox="551 475 1648 1385"> <thead> <tr> <th>Regimens</th> <th>Total CRC Patients</th> <th>Metastatic CRC Patients</th> </tr> </thead> <tbody> <tr> <td>Aflibercept plus chemotherapy</td> <td>0</td> <td>0</td> </tr> <tr> <td>Bevacizumab plus fluoropyrimidine-based chemotherapy</td> <td>0</td> <td>0</td> </tr> <tr> <td>Capecitabine</td> <td>6</td> <td>0</td> </tr> <tr> <td>CAPIRI</td> <td>0</td> <td>0</td> </tr> <tr> <td>CAPOX</td> <td>0</td> <td>0</td> </tr> <tr> <td>Cetuximab with FOLFIRI</td> <td>0</td> <td>0</td> </tr> <tr> <td>Cetuximab with FOLFOX</td> <td>0</td> <td>0</td> </tr> <tr> <td>Cetuximab as a single agent</td> <td>0</td> <td>0</td> </tr> <tr> <td>Cetuximab with Encorafenib</td> <td>0</td> <td>0</td> </tr> <tr> <td>Irinotecan as a single agent</td> <td>0</td> <td>0</td> </tr> <tr> <td>FOLFIRI</td> <td>0</td> <td>0</td> </tr> <tr> <td>FOLFOX</td> <td>0</td> <td>0</td> </tr> <tr> <td>Fluorouracil (5FU) as a single agent</td> <td>0</td> <td>0</td> </tr> <tr> <td>Oxaliplatin as a single agent</td> <td>0</td> <td>0</td> </tr> <tr> <td>Nivolumab with Ipilimumab</td> <td>0</td> <td>0</td> </tr> <tr> <td>Panitumumab with FOLFIRI</td> <td>0</td> <td>0</td> </tr> </tbody> </table>	Regimens	Total CRC Patients	Metastatic CRC Patients	Aflibercept plus chemotherapy	0	0	Bevacizumab plus fluoropyrimidine-based chemotherapy	0	0	Capecitabine	6	0	CAPIRI	0	0	CAPOX	0	0	Cetuximab with FOLFIRI	0	0	Cetuximab with FOLFOX	0	0	Cetuximab as a single agent	0	0	Cetuximab with Encorafenib	0	0	Irinotecan as a single agent	0	0	FOLFIRI	0	0	FOLFOX	0	0	Fluorouracil (5FU) as a single agent	0	0	Oxaliplatin as a single agent	0	0	Nivolumab with Ipilimumab	0	0	Panitumumab with FOLFIRI	0	0			
Regimens	Total																																																																																																		
CRC Patients	Metastatic																																																																																																		
CRC Patients																																																																																																			
Aflibercept plus chemotherapy																																																																																																			
Bevacizumab plus fluoropyrimidine-based chemotherapy																																																																																																			
Capecitabine																																																																																																			
CAPIRI																																																																																																			
CAPOX																																																																																																			
Cetuximab with FOLFIRI																																																																																																			
Cetuximab with FOLFOX																																																																																																			
Cetuximab as a single agent																																																																																																			
Cetuximab with Encorafenib																																																																																																			
Irinotecan as a single agent																																																																																																			
FOLFIRI																																																																																																			
FOLFOX																																																																																																			
Fluorouracil (5FU) as a single agent																																																																																																			
Oxaliplatin as a single agent																																																																																																			
Nivolumab with Ipilimumab																																																																																																			
Panitumumab with FOLFIRI																																																																																																			
Panitumumab with FOLFOX																																																																																																			
Panitumumab as a single agent																																																																																																			
Pembrolizumab																																																																																																			
Regimens	Total CRC Patients	Metastatic CRC Patients																																																																																																	
Aflibercept plus chemotherapy	0	0																																																																																																	
Bevacizumab plus fluoropyrimidine-based chemotherapy	0	0																																																																																																	
Capecitabine	6	0																																																																																																	
CAPIRI	0	0																																																																																																	
CAPOX	0	0																																																																																																	
Cetuximab with FOLFIRI	0	0																																																																																																	
Cetuximab with FOLFOX	0	0																																																																																																	
Cetuximab as a single agent	0	0																																																																																																	
Cetuximab with Encorafenib	0	0																																																																																																	
Irinotecan as a single agent	0	0																																																																																																	
FOLFIRI	0	0																																																																																																	
FOLFOX	0	0																																																																																																	
Fluorouracil (5FU) as a single agent	0	0																																																																																																	
Oxaliplatin as a single agent	0	0																																																																																																	
Nivolumab with Ipilimumab	0	0																																																																																																	
Panitumumab with FOLFIRI	0	0																																																																																																	

Any other systemic anti-cancer therapy Palliative care only	Panitumumab with FOLFOX	0	0			
	Panitumumab as a single agent	0	0			
	Pembrolizumab	0	0			
	Any other systemic anti-cancer therapy	0	0			
	Palliative care only	0	0			

I trust this information answers your request. Should you have any further enquiries or queries about this response please do not hesitate to contact me. However, if you are unhappy with the way in which your request has been handled, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Sally Brook Shanahan, Director of Corporate Affairs, King's Mill Hospital, Mansfield Road, Sutton in Ashfield, Nottinghamshire, NG17 4JL or email sally.brookshanahan@nhs.net.

If you are dissatisfied with the outcome of the internal review, you can apply to the Information Commissioner's Office, who will consider whether we have complied with our obligations under the Act and can require us to remedy any problems. Generally, the Information Commissioner's Office cannot decide unless you have exhausted the internal review procedure. You can find out more about how to do this, and about the Act in general, on the Information Commissioner's Office website at: <https://ico.org.uk/your-data-matters/official-information/>.

Complaints to the Information Commissioner's Office should be sent to FOI/EIR Complaints Resolution, Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. Telephone 0303 1231113, email casework@ico.org.uk.

If you would like this letter or information in an alternative format, for example large print or easy read, or if you need help with communicating with us, for example because you use British Sign Language, please let us know. You can call us on 01623 672232 or email sfh-tr.foi.requests@nhs.net.

Yours faithfully

Information Governance Team

All information we have provided is subject to the provisions of the Re-use of Public Sector Information Regulations 2015. Accordingly, if the information has been made available for re-use under the [Open Government Licence](#) (OGL) a request to re-use is not required, but the licence conditions must be met. You must not re-use any previously unreleased information without having the consent from Sherwood Forest Hospitals NHS Foundation Trust. Should you wish to re-use previously unreleased information then you must make your request in writing. All requests for re-use will be responded to within 20 working days of receipt.